Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Lyketsos

Showing results (301-310 of 396) with videos related to

Pageof 40
Sort By:
International Psychogeriatrics|February 22, 2008
Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's disease: the Cache County StudyKatherine A Treiber, Constantine G Lyketsos, Chris Corcoran, et al.
Archives of Neurology|March 15, 2006
Antihypertensive medication use and incident Alzheimer disease: the Cache County StudyAra S Khachaturian, Peter P Zandi, Constantine G Lyketsos, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|January 8, 2013
Caregiver coping strategies predict cognitive and functional decline in dementia: the Cache County Dementia Progression StudyJoAnn T Tschanz, Kathleen Piercy, Chris D Corcoran, et al.
International Journal of Geriatric Psychiatry|January 22, 2005
Clinical application of operationalized criteria for 'Depression of Alzheimer's Disease'Paul B Rosenberg, Chiadi U Onyike, Ira R Katz, et al.
Frontiers in Neurology|September 10, 2011
Multi-modal MRI analysis with disease-specific spatial filtering: initial testing to predict mild cognitive impairment patients who convert to Alzheimer's diseaseKenichi Oishi, Kazi Akhter, Michelle Mielke, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 4, 2010
Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume lossMichelle M Mielke, Norman J Haughey, Veera Venkata Ratnam Bandaru, et al.
Nature Medicine|March 26, 2025
Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trialTarek K Rajji, Sheriza N Baksh, David M Shade, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 28, 2015
A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitationAyman Akil, Robert R Bies, Bruce G Pollock, et al.
The American Journal of Psychiatry|April 17, 2009
Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD studyLing Zheng, Wendy J Mack, Karen S Dagerman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 24, 2015
Dementia severity and the longitudinal costs of informal care in the Cache County populationGail B Rattinger, Sarah Schwartz, C Daniel Mullins, et al.
Pageof 40

Showing results (301-310 of 396) with videos related to

Sort By:
Pageof 40
International Psychogeriatrics|February 22, 2008
Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's disease: the Cache County StudyKatherine A Treiber, Constantine G Lyketsos, Chris Corcoran, et al.
Archives of Neurology|March 15, 2006
Antihypertensive medication use and incident Alzheimer disease: the Cache County StudyAra S Khachaturian, Peter P Zandi, Constantine G Lyketsos, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|January 8, 2013
Caregiver coping strategies predict cognitive and functional decline in dementia: the Cache County Dementia Progression StudyJoAnn T Tschanz, Kathleen Piercy, Chris D Corcoran, et al.
International Journal of Geriatric Psychiatry|January 22, 2005
Clinical application of operationalized criteria for 'Depression of Alzheimer's Disease'Paul B Rosenberg, Chiadi U Onyike, Ira R Katz, et al.
Frontiers in Neurology|September 10, 2011
Multi-modal MRI analysis with disease-specific spatial filtering: initial testing to predict mild cognitive impairment patients who convert to Alzheimer's diseaseKenichi Oishi, Kazi Akhter, Michelle Mielke, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 4, 2010
Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume lossMichelle M Mielke, Norman J Haughey, Veera Venkata Ratnam Bandaru, et al.
Nature Medicine|March 26, 2025
Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trialTarek K Rajji, Sheriza N Baksh, David M Shade, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 28, 2015
A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitationAyman Akil, Robert R Bies, Bruce G Pollock, et al.
The American Journal of Psychiatry|April 17, 2009
Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD studyLing Zheng, Wendy J Mack, Karen S Dagerman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 24, 2015
Dementia severity and the longitudinal costs of informal care in the Cache County populationGail B Rattinger, Sarah Schwartz, C Daniel Mullins, et al.
Pageof 40